

Neratinib NALA

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



No QoL benefit

Serious and disabling adverse effects



Increased toxicity

Other adjustments



Neratinib NALA

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Treatment of HER2-positive breast cancer patients who have received two or more prior anti-HER2 based regimens in the metastatic setting
 Experimental Arm: Neratinib + Capecitabine
 Control Arm: Lapatinib plus capecitabine

